Pain is passé in Blood Test, thanks to Metropolis’ Human Touch

New Delhi: Blood drawing for test has really reached proverbial ant bite, thanks to introduction of innovative blood collection technology by Metropolis healthcare, India’s second largest pathology laboratory chain. First of kind technology named UltraTouch™ Push Button Blood Collection Set (PBBCS) minimizes pain and, in turn, needle anxiety. Pain in the process may be overrated but, despite ant bite assurance, most people flinch when needle pierces. For lot of people even thought of it is traumatic.

So far as pain during piercing of needle to draw blood is concerned, Ameera Shah-led Metropolis Healthcare Limited has become a cut above the rest due to this new technology. This will for sure improve patient experience of the process across its service network.  This state-of-the-art device features a thinner needle that reduces insertion pain and makes blood collection more comfortable for first-time patients, children, and the elderly. Aligned with Metropolis’ mission to improve patient care, this innovative approach aims to make the blood collection process quicker, safer, and less cumbersome for people of all ages.

Surendran Chemmenkotil, Chief Executive Officer says, ‘The UltraTouch™ PBBCS represents a significant advancement in patient comfort and safety during blood collection, while also ensuring the accuracy of our results. By leveraging this cutting-edge technology, we are addressing gaps in diagnostics to enhance the overall patient experience.”

Blood tests are crucial for over 70 per cent of medical decisions; however, many patients hesitate due to concerns about pain. Even studies indicate that nearly 80 percent of patients believe their blood draw experience significantly impacts their overall satisfaction with healthcare providers.

A recent study published in the Journal of Evolution of Medical and Dental Sciences (JEMDS) evaluated the impact of the UltraTouch™ PBBCS at Metropolis Healthcare’s Global Reference Laboratory in Mumbai over a one-month period. Over 90% of participants reported minimal discomfort with no signs of hemolysis, leading to an improved overall experience. The laboratory parameters of potassium, iron, and haemoglobin levels also remained consistent. This assessment involved a diverse group of adult participants, focusing on the device’s effectiveness in reducing pain and ensuring the reliability of blood samples and needle injuries.

Kannan Alangadan, Chief Operating Officer, said, ‘As someone deeply involved in patient care, I understand the anxiety that often accompanies with blood collection, At Metropolis, our focus is on elevating the patient experience through innovative technology and compassionate care. Our dedicated phlebotomists and technicians are committed to delivering exceptional service across our network. With a leading Net Promoter Score of 87, we continually prioritize patient comfort and satisfaction in every interaction.’

In addition to prioritizing patient comfort, the innovative blood collection system is designed to improve efficiency within laboratories. By reducing the time required for blood draws and minimizing the risk of complications, Metropolis Healthcare can ensure faster turnaround times for test results, ultimately benefiting patient care.

Related Posts

Ship of Domestic Medical Device Industry flounders, thanks to Israel-Iran War

Association of Indian Medical Device Industry (AiMeD) sends SOS to Union Minister Piyush Goel New Delhi: The war tremors have started shaking the domestic medical device industry perched on the…

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Dr D S Rana, Chairman, Sir Ganga Ram Trust Society was Cynosure of all Eyes New Delhi: Inaugural Conference of Critical Nephrology Society of India CNSICON 26 under the aegis…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Diabetic drug metformin found to act on brain

Diabetic drug metformin found to act on brain

Hetero debuts semaglutide generic in emerging markets

Hetero debuts semaglutide generic in emerging markets

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework